Regulus Therapeutics (RGLS) – Company Press Releases
-
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
-
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
-
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant
-
Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polyc
-
Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
-
Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates
-
Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Diseas
-
Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
-
Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant
-
Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Poly
-
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
-
Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023
-
Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates
-
Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
-
Regulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conference
-
Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disea
-
Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors
-
Regulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard's Brigham and Women's Hospital
-
Regulus Therapeutics Strengthens Research & Development Leadership
-
Regulus Therapeutics Advances to Cohort 2 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
-
Regulus Therapeutics Reports First Quarter 2023 Financial Results and Recent Updates
-
Regulus Therapeutics Announces $15 Million Private Placement of Equity
-
Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polyc
-
Regulus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Updates
-
Regulus Therapeutics to Present at the SVB Securities Global Biopharma Conference
-
Regulus Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Regulus Therapeutics Announces Resignation of Board Member
-
Regulus Therapeutics Announces Appointments of Industry Veterans, Drs. Rekha Garg and Claire Padgett, to Lead Clinical Development, Regulatory and Clinical Operations
-
Regulus Therapeutics Reports Third Quarter 2022 Financial Results and Recent Updates
-
Regulus Therapeutics Announces Timing for Third Quarter 2022 Financial Results Webcast and Conference Call
-
Regulus Therapeutics Announces First Patient Dosed in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
-
Regulus Therapeutics Announces Poster Presentation at ASN Kidney Week 2022
-
Regulus Therapeutics Announces Positive Topline Safety and Pharmacokinetic (PK) Data from the Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the treatment of Autosomal Dominant Pol
-
Regulus Therapeutics to Participate in Upcoming Investor Conferences
-
Regulus Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates
-
Regulus Therapeutics Announces Timing for Second Quarter 2022 Financial Results Webcast and Conference Call
-
Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
-
Regulus Therapeutics Announces First Subject Dosed in Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
-
Regulus Appoints Amin Kamel, Ph.D., as Vice President, DMPK
-
Regulus Therapeutics to Present at the H.C. Wainwright Global Investment Conference
-
Regulus Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates
-
Regulus Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
-
Regulus Therapeutics Announces Timing for First Quarter 2022 Financial Results Webcast and Conference Call
-
Regulus Therapeutics Announces Initiation of Preclinical Studies in Amyotrophic Lateral Sclerosis under a Collaboration Agreement with Harvard's Brigham and Women's Hospital
-
Regulus Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Updates
-
Regulus Therapeutics Announces Timing for Fourth Quarter and Year-End 2021 Financial Results Webcast and Conference Call
-
Regulus Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Lademirsen for Alport Syndrome
-
Regulus Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
-
Regulus Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA for RGLS8429
-
Regulus Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference
Back to RGLS Stock Lookup
